Loading clinical trials...

Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution

Patients With ALS and Other Motor Discorders Will be Treated With Mesenchymal Cell Exosome Solution

NCT07105371•The Foundation for Orthopaedics and Regenerative Medicine

View on ClinicalTrials.gov

Summary

Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.

Detailed Description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients will need a diagnosis established by a neurologist. Patients must be able to provide informed consent, or have a guardian who does. They must be able to travel to the site of treatment.

Exclusion Criteria

•Patients were excluded from the trial if they were pregnant or had active cancer at the screening consultation.

Locations (1)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Key Dates

Start Date

July 14, 2024

Primary Completion Date

March 14, 2025

Completion Date

March 14, 2025

Last Updated

August 22, 2025

Enrollment

ACTUAL participants

Conditions

Motor Disorders

Interventions

AlloEx exosomes

BIOLOGICAL

Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.

NCT07095062

Friedreich's AtaxiaMotor Disorders

View study

RECRUITING

Combined Artificial Intelligence and Mobile Application for Remote Infant Motor Screening: Development and Validation

NCT06521918

Motor Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution

Inclusion Criteria

Exclusion Criteria

Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.

Combined Artificial Intelligence and Mobile Application for Remote Infant Motor Screening: Development and Validation

A Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease

Accuracy Comparison: Optoelectronic Motion Capture and Markerless System

Motor Control Prevention Strategies in Basketball Players

Neuromotor Development and Motor Related Health Care in Children with a High Risk Neonatal Period